Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents

Inflammatory Bowel Disease

Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel Disease

Inflamm Bowel Dis.

Neto MBB, Gregory MH, Ramos GP, Bazerbachi F, Bruining DH, Abu Dayyeh BK, Kushnir VM, Raffals LE, Ciorba MA, Loftus EV, Deepak P

doi: 10.1093/ibd/izz236.

Inflammatory Bowel Disease

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Therap Adv Gastroenterol.

Grob L, Bluemel S, Biedermann L, Fournier N, Rossel JB, Vavricka SR, Zeitz J, Rogler G, Stallmach A, Scharl M

doi: 10.1177/1756284819895217.

Inflammatory Bowel Disease

The Unique Disease Course of Children with Very Early onset-Inflammatory Bowel Disease

Inflamm Bowel Dis.

Kelsen JR, Conrad MA, Dawany N, Patel T, Shraim R, Merz A, Maurer K, Sullivan KE, Devoto M

doi: 10.1093/ibd/izz214.

Inflammatory Bowel Disease

Case-matched comparison of postoperative outcomes following surgery for inflammatory bowel disease after exposure to vedolizumab vs. other biologics

J Crohns Colitis.

Novello M, Stocchi L, Steele SR, Holubar SD, Duraes LC, Kessler H, Shawki S, Hull LT

doi: 10.1093/ecco-jcc/jjz129.

Inflammatory Bowel Disease

Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases

Inflamm Bowel Dis.

Attauabi M, Zhao M, Bendtsen F, Burisch J

doi: 10.1093/ibd/izaa167.

RECOMMENDED

Inflammatory Bowel Disease

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Clin Gastroenterol Hepatol.

Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Casteele NV, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA

doi: 10.1016/j.cgh.

Inflammatory Bowel Disease

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Inflamm Bowel Dis.

Chen C, Hartzema AG, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O, Glover SC, Zimmermann EM

doi: 10.1093/ibd/izz001.

Inflammatory Bowel Disease

Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland

Eur J Gastroenterol Hepatol.

Guilcher K, Fournier N, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A; Swiss IBD Cohort Study

doi: 10.1097/

RECOMMENDED

Inflammatory Bowel Disease

Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort - an Epi-IBD study

doi: 10.1111/jgh.14563.

Related content

Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel Disease

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

The Unique Disease Course of Children with Very Early onset-Inflammatory Bowel Disease

Case-matched comparison of postoperative outcomes following surgery for inflammatory bowel disease after exposure to vedolizumab vs. other biologics

Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland

Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort - an Epi-IBD study